"Emend" redirects here. For "Emend for Injection", see Fosaprepitant.
Structural formula of aprepitant
Ball-and-stick model of the aprepitant molecule
Clinical data
Trade names Emend
AHFS/Drugs.com Monograph
MedlinePlus a604003
  • AU: B1
  • US: B (No risk in non-human studies)
Routes of
Oral (capsules)
ATC code A04AD12 (WHO)
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
Pharmacokinetic data
Bioavailability 60–65%
Protein binding >95%
Metabolism Hepatic (mostly CYP3A4- mediated; some contributions by CYP2C19 & CYP1A2)
Biological half-life 9–13 hours
Excretion Urine (5%), faeces (86%)
CAS Number 170729-80-3 YesY
PubChem (CID) 6918365
DrugBank DB00673 YesY
ChemSpider 5293568 YesY
ChEBI CHEBI:499361 YesY
Chemical and physical data
Formula C23H21F7N4O3
Molar mass 534.427 g/mol
3D model (Jmol) Interactive image

Aprepitant (brand name: Emend (the brand name used in all English-speaking countries)) is an antiemetic chemical compound that belongs to a class of drugs called substance P antagonists (SPA). It mediates its effect by blocking the neurokinin 1 (NK1) receptor.

Aprepitant is manufactured by Merck & Co. under the brand name Emend for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting. It was approved by the FDA in 2003.[1]

Aprepitant may also be useful in the treatment of cyclic vomiting syndrome and late-stage chemotherapy induced vomiting, but there are few studies to date.

On January 2008, the FDA approved fosaprepitant, an intravenous form of aprepitant, which is to be sold under the tradename Emend Injection in the US and as Ivemend in some other countries.

Structure and properties

Aprepitant is made up of a morpholine core with two substituents attached to adjacent ring carbons. These substitute groups are trifluoromethylated phenyl ethanol and fluorophenyl group. Aprepitant also has a third substituent (triazolinone), which is joined to the morpholine ring nitrogen. It has three chiral centres very close together, which combine to produce an amino acetal arrangement. Its empirical formula is C23H21F7N4O3.

Aprepitant is an off-white crystalline solid that has a molecular weight of around 534.53. It has a very limited solubility in water. It does have a reasonably high solubility in non-polar molecules such as oils. This would, therefore, suggest that aprepitant as a whole, despite having components that are polar, is a non-polar substance.


Shortly after Merck initiated research into the reducing the severity and likelihood of CINV, researchers discovered that aprepitant is effective in prevention. Researchers worked on coming up with a process to create aprepitant, and within a short period they came up with effective synthesis of the substance. This original synthesis was deemed to be workable and proved to be a crucial step in achieving commercialization; however, Merck decided that the process was not environmentally sustainable. This was due to the original synthesis requiring six steps, many of which needed dangerous chemicals such as sodium cyanide, dimethyltitanocene, and gaseous ammonia. In addition to this, for the process to be effective cryogenic temperatures were needed for some of the steps and other steps produced hazardous by products such as methane and magnesium chloride.[2] The environmental concerns of the synthesis of aprepitant became so great that Merck research team decided to withdraw the drug from clinical trials and attempt to create a different synthesis of aprepitant.[3]

The gamble of taking the drug out of clinical trials proved to be successful when shortly afterwards the team of Merck researchers came up with an alternative and more environmentally friendly synthesis of aprepitant. The new process works by four compounds of similar size and complexity being fused together. This therefore is a much simpler process and requires only three steps, half the number of the original synthesis.

The new process begins by enantiopure trifluoromethylated phenyl ethanol being joined to a racemic morpholine precursor. This results in the wanted isomer crystallizing on the top of the solution and the unwanted isomer remaining in the solution. The unwanted isomer is then converted to the wanted one by the chemist controlling the reaction conditions and a process known as crystallization-induced asymmetric transformation occurring. By the end of this step a secondary amine, the base of the drug, is formed.

The second step involves the fluorophenyl group being attached to the morpholine ring. Once this has been achieved the third and final step can initiated. This step involved a side chain of triazolinone being added to the ring. Once this step has been successfully completed a stable molecule of aprepitant has been produced.[4]

This more streamlined route yields around 76% more aprepitant than the original process and reduces the operating cost by a significant amount. In addition, the new process also reduces the amount of solvent and reagents required by about 80% and saving an estimated 340,000L per ton of aprepitant produced.[3]

The improvements in the synthesis process have also resulted in a decrease in the number long-term detrimental to the natural environment, due to elimination of hazardous chemicals from the procedure of this technique

Mechanism of action

Aprepitant is classified as an NK1 antagonist because it blocks signals given off by NK1 receptors. This, therefore, decreases the likelihood of vomiting in patients.

NK1 is a G protein-coupled receptor located in the central and peripheral nervous system. This receptor has a dominant ligand known as Substance P (SP). SP is a neuropeptide, composed of 11 amino acids, which sends impulses and messages from the brain. It is found in high concentrations in the vomiting center of the brain, and, when activated, it results in a vomiting reflex. In addition to this it also plays a key part in the transmission of pain impulses from the peripheral receptors to the central nervous system.

Aprepitant has been shown to inhibit both the acute and delayed emesis induced by cytotoxic chemotherapeutic drugs by blocking substance P landing on receptors in the brain's neurons. Positron emission tomography (PET) studies, have demonstrated that aprepitant can cross the blood brain barrier and bind to NK1 receptors in the human brain.[5] It has also been shown to increase the activity of the 5-HT3 receptor antagonists ondansetron and the corticosteroid dexamethasone, which are also used to prevent nausea and vomiting caused by chemotherapy.[6]

Aprepitant is taken orally in the form of a capsule. Before clinical testing, a new class of therapeutic agent has to be characterized in terms of preclinical metabolism and excretion studies. Average bioavailability is found to be around 60-65%. Aprepitant is metabolized primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19. Seven metabolites of aprepitant, which are only weakly active, have been identified in human plasma. As a moderate inhibitor of CYP3A4, aprepitant can increase plasma concentrations of co-administered medicinal products that are metabolized through CYP3A4. Specific interaction has been demonstrated with oxycodone, where aprepitant both increased the efficacy and worsened the side effects of oxycodone; however it is unclear whether this is due to CPY3A4 inhibition or through its NK-1 antagonist action.[7] Following IV administration of a 14C-labeled prodrug of aprepitant (L-758298), which is converted rapidly and completely to aprepitant, approximately 57% of the total radioactivity is excreted in the urine and 45% in feces. No unchanged substance is excreted in urine.[8]

One of the main features of aprepitant, and a major advantage it has over other chemotherapy-induced side-effect treatments, is its ability to selectively antagonize NK1 receptors, while having very low affinity to other common receptors such as serotonin, dopamine, and corticosteroid. It is estimated that aprepitant is at least 3,000 times more selective to NK1 receptors compared to these other enzyme transporter, ion channels. The normal dosing of aprepitant given as 125 mg in the first day after chemotherapy and followed by 80 mg the following 2 days.

Other uses

Major Depression

Encouraged by positive results in their early controlled studies of aprepitant (300 mg/d with enforced food intake) [9] and L-759,274[10](another NK1 receptor antagonist), as well as those of CP-122,721 (Pfizer)[11] in patients with major depressive disorder, Merck & Co. conducted Phase III clinical trials on aprepitant in which patients received 80 mg or 160 mg/d (a new formulation, prescribed without enforced food intake) as a treatment for major depressive disorder. Despite achieving 90-95% receptor occupancy of aprepitant in certain brain regions, negative clinical results were observed in three actively controlled studies.[12] The company has since abandoned plans to market aprepitant 160 mg as an antidepressant. Subsequently, large clinically positive double blind controlled studies with two additional NK1 receptor antagonists, casopitant,[13] and orvepitant [14] (both GlaxoSmithKine compounds)[15] have been published in peer reviewed medical journals. This work now replicates the early findings of Merck and Co with aprepitant and L-759,274, and of Pfizer with CP-122,721. Arguably, the weight of preclinical data[16] and unambiguous positive clinical evidence (in over 2000 patients studied in five well-controlled RCTs, of five separate compounds [three tested at 2 or more dose levels] conducted by three independent labs) provides critical evidence that NK1 receptor antagonism, including that of aprepitant, is an authentically distinct antidepressant mechanism. Across all these studies, efficacy appeared to be dose-related. Only mild, transient, and tolerable side effects, not those typically observed with either the SSRI, SNRI, or NRI classes of antidepressants, have been observed.

Beyond suggestions that PET receptor occupancy must not be used routinely to cap dosing for new medical indications for this class,[17] or that > 99% human receptor occupancy might be required for consistent psycho-pharmacological or other therapeutic effects,[15] critical scientific dissection and debate of the above data might be needed to enable aprepitant, and the class of NK1 antagonists as a whole, to fulfill preclinically predicted utilities beyond CINV (i.e., for other psychiatric disorders, addictions, neuropathic pain, migraine, osteoarthritis, overactive bladder, inflammatory bowel disease, and other disorders with suspected inflammatory or immunological components (see anti-cancer below.) However, most data remain proprietary and thus reviews on the expanded clinical potential for drugs like aprepitant range from optimistic[18] to crepe-hanging.[19]

See also


  1. "Drug Approval Package: EMEND (Aprepitant) NDA #21-549". Retrieved 2011-04-19.
  2. Structural Optimization Affording 2-(R)-(1-(R)-3,5-Bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a Potent, Orally Active, Long-Acting Morpholine Acetal Human NK-1 Receptor Antagonist. J. Med. Chem, (1998) Volume 41, Issue 23, Pages 4607-4614
  3. 1 2 Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Annals of the New York Academy of Sciences, (2011) Volume 1222, Pages 40-48
  4. Efficient Synthesis of NK1 Receptor Antagonist Aprepitant Using a Crystallization-Induced Diastereoselective Transformation. J. Am. Chem. Soc., (2003) Volume 125, Issue 8, Pages 2129-2135
  5. "Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant". Biological Psychiatry. 55: 1007–1012. doi:10.1016/j.biopsych.2004.02.007.
  6. Gralla R, de Wit R, Herrstedt J, Carides A, Ianus J, Guoguang-Ma J, Evans J, Horgan K (2005). "Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials". Cancer. 104 (4): 864–8. doi:10.1002/cncr.21222. PMID 15973669.
  7. Walsh, S. L.; Heilig, M.; Nuzzo, P. A.; Henderson, P.; Lofwall, M. R. (2012). "Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers". Addiction Biology. 18: no. doi:10.1111/j.1369-1600.2011.00419.x.
  8. FDA Advisory Committee Background Package
  9. Kramer, MS; Cutler, N; Feighner, J; Shrivastava, R; Carman, J; Sramek, JJ; Reines, SA; Liu, G; Snavely, D; Wyatt-Knowles, E; Hale, JJ; Mills, SG; MacCoss, M; Swain, CJ; Harrison, T; Hill, RG; Hefti, F; Scolnick, EM; Cascieri, MA; Chicchi, GG; Sadowski, S; Williams, AR; Hewson, L; Smith, D; Carlson, EJ; Hargreaves, RJ; Rupniak, NM (1998). "Distinct mechanism for antidepressant activity by blockade of central substance P receptors". Science. 281: 1640–5. doi:10.1126/science.281.5383.1640. PMID 9733503.
  10. Kramer, M. S.; Winokur, A; Kelsey, J; Preskorn, S. H.; Rothschild, A. J.; Snavely, D; Ghosh, K; Ball, W. A.; Reines, S. A.; Munjack, D; Apter, J. T.; Cunningham, L; Kling, M; Bari, M; Getson, A; Lee, Y (2004). "Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression". Neuropsychopharmacology. 29 (2): 385–92. doi:10.1038/sj.npp.1300260. PMID 14666114.
  11. McLean, S (2005). "Do substance P and the NK1 receptor have a role in depression and anxiety?". Current pharmaceutical design. 11 (12): 1529–47. doi:10.2174/1381612053764779. PMID 15892660.
  12. Keller, Martin; Montgomery, Stuart; Ball, William; Morrison, Mary; Snavely, Duane; Liu, Guanghan; Hargreaves, Richard; Hietala, Jarmo; Lines, Christopher; Beebe, Katherine; Reines, Scott (2006). "Lack of Efficacy of the Substance P (Neurokinin1 Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder". Biological Psychiatry. 59 (3): 216–23. doi:10.1016/j.biopsych.2005.07.013. PMID 16248986.
  13. Ratti, E; Bellew, K; Bettica, P; Bryson, H; Zamuner, S; Archer, G; Squassante, L; Bye, A; Trist, D; Krishnan, K. R.; Fernandes, S (2011). "Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder". Journal of Clinical Psychopharmacology. 31 (6): 727–33. doi:10.1097/JCP.0b013e31823608ca. PMID 22020354.
  14. Trist, DG; Ratti, E; Bye, A (2013). "Why receptor reserve matters for neurokinin1 (NK1) receptor antagonists". J. Recept. Signal Transduct. Res. 33: 333–7. doi:10.3109/10799893.2013.843194. PMID 24106886.
  15. 1 2 Ratti, E; Bettica, P; Alexander, R; Archer, G; Carpenter, D; Evoniuk, G; Gomeni, R; Lawson, E; Lopez, M; Millns, H; Rabiner, E. A.; Trist, D; Trower, M; Zamuner, S; Krishnan, R; Fava, M (2013). "Full central neurokinin-1 receptor blockade is required for efficacy in depression: Evidence from orvepitant clinical studies". Journal of Psychopharmacology. 27 (5): 424–34. doi:10.1177/0269881113480990. PMID 23539641.
  16. Ebner, K; Singewald, N (2006). "The role of substance P in stress and anxiety responses". Amino Acids. 31 (3): 251–72. doi:10.1007/s00726-006-0335-9. PMID 16820980.
  17. Barrett, J. S.; McGuire, J; Vezina, H; Spitsin, S; Douglas, S. D. (2013). "PET measurement of receptor occupancy as a tool to guide dose selection in neuropharmacology: Are we asking the right questions?". Journal of Clinical Psychopharmacology. 33 (6): 725–8. doi:10.1097/JCP.0b013e3182a88654. PMID 24100788.
  18. Herpfer, I; Lieb, K (2005). "Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential.". CNS drugs. 19 (4): 275–93. PMID 15813642.
  19. "Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?". Nature Reviews Drug Discovery. 11: 462–478. doi:10.1038/nrd3702.

External links

This article is issued from Wikipedia - version of the 10/30/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.